Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis

Cancer Survivorship, Atlanta (GA): Center for disease Control and Prevention (US), national Center for Chronic disease Prevention and health Promotion. http://www.cdc.gov/cancer/survivorship/pdf/survivorship_fs.pdf(Accessed 23 May 2018). Pfreundschuh, 2006, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised con- trolled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, 379, 10.1016/S1470-2045(06)70664-7 Pfreundschuh, 2011, CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group, Lancet Oncol, 12, 1013, 10.1016/S1470-2045(11)70235-2 Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, 235, 10.1056/NEJMoa011795 Coiffier, 2010, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte, Blood, 116, 2040, 10.1182/blood-2010-03-276246 Mauch, 1994, Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease, Cancer J Sci Am, 1, 33 Ng, 2002, Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger, J Clin Oncol, 20, 2101, 10.1200/JCO.2002.08.021 ICD-O-3: International Classification of Diseases for Oncology. 3. Geneva: World Health Organization; Available from 2000. Clarke, 2004, Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications, Cancer Epidemiol Biomarkers Prev, 13, 138, 10.1158/1055-9965.EPI-03-0250 Sabattini, 2008, WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. International Agency for Research on Cancer, Blood, 102, 83 Warren, 1932, Multiple primary malignant tumors: a survey of the literature and a statistical study, Am J Cancer, 16, 1358 Breslow, 1987, Vol. 2 Schaapveld, 2015, Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, N Engl J Med, 373, 2499, 10.1056/NEJMoa1505949 Chowdhry, 2015, Second primary head and neck cancer after hodgkin lymphoma : a population-based study of 44, 879 survivors of Hodgkin lymphoma, Cancer, 121, 1436, 10.1002/cncr.29231 Morton, 2010, Second malignancy risks after non-hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype, J Clin Oncol, 28, 4935, 10.1200/JCO.2010.29.1112 E.A. Engels, R.J. Biggar, H.I. Hall, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer123(2008) 187–194. Intaraphet, 2017, Human papillomavirus infection and lymphoma incidence using cervical conization as a surrogate marker: a Danish nationwide cohort study, Hematol Oncol, 35, 172, 10.1002/hon.2270 Park, 2012, Limitations and biases of the surveillance, epidemiology, and end results database, Curr Probl Cancer, 36, 216, 10.1016/j.currproblcancer.2012.03.011 Curtis, 2006 Noone, 2016, Comparison of SEER treatment data with Medicare claims, Med Care, 54, e55, 10.1097/MLR.0000000000000073